Skip to main content
PLOS One logoLink to PLOS One
. 2022 Aug 5;17(8):e0272310. doi: 10.1371/journal.pone.0272310

Effect of Zanthoxylum bungeanum essential oil on rumen enzyme activity, microbiome, and metabolites in lambs

Hailong Zhang 1,2, Xia Lang 2,3, Xiao Li 1, Guoshun Chen 1,*, Cailian Wang 2,3,*
Editor: Chun Wie Chong4
PMCID: PMC9355197  PMID: 35930558

Abstract

Antibiotics were once used in animal production to improve productivity and resistance to pathogenic microbiota. However, due to its negative effects, the search for a new class of substances that can replace its efficacy has become one of the urgent problems to be solved. Plant essential oils (EOs) as a natural feed additive can maintain microbiota homeostasis and improve animal performance. However, its specific mechanism of action needs to be further investigated. Therefore, we added different doses of essential oil of Zanthoxylum bungeanum (EOZB) to the diets of Small Tail Han Sheep hybrid male lambs (STH lambs) to evaluate the effect of EOZB on rumen enzyme activity, rumen microbiology, and its metabolites in STH lambs. Twenty STH lambs were randomly divided into four groups (n = 5/group) and provided with the same diet. The dietary treatments were as follows: basal diet (BD) group; BD+EOZB 5 ml/kg group; BD+EOZB 10 ml/kg group; BD+EOZB 15 ml/kg group. We found that EOZB 10 ml/kg helped to increase rumen pectinase (P<0.05) and lipase (P<0.05) activities. Microbial 16S rRNA gene analysis showed that EOZB significantly altered the abundance of rumen microbiota (P<0.05). LC/GC-MS metabolomic analysis showed that the addition of EOZB produced a total of 1073 differential metabolites, with 58 differential metabolites remaining after raising the screening criteria. These differential metabolites were mainly enriched in glycerophospholipid metabolism, choline metabolism in cancer, retrograde endocannabinoid signaling, benzoxazinoid biosynthesis, and protein digestion and absorption. Correlation analysis showed that some rumen microbiota were significantly correlated with differential metabolite and enzyme activities.

Introduction

Microbiota is vital to the health of the host [1]. The mammalian gastrointestinal tract is inhabited by 1013 to 1014 microbiota that plays an important role in host immune regulation, nutrient metabolism, maintenance of the structural integrity of the intestinal barrier, and defense against pathogens [2, 3]. The homeostasis of the gastrointestinal microbiota is relevant to host health [4, 5]. In animal production, plant EOs are used as a natural feed additive to maintain microbiota homeostasis and improve animal performance [68]. However, its specific mechanism of action needs to be further investigated.

Antibiotics were once used in animal production to improve animal productivity and maintain health status. However, due to their negative effects such as drug resistance and food safety concerns, other strategies have been attempted to improve animal growth performance and immune function [9]. For example, astragalus by-products had beneficial effects on rumen fermentation patterns and lipid metabolism in sheep, with no negative effects on their production performance and humoral immunity [10]. Direct feeding of probiotics to cows stabilizes rumen pH, the reduction in CH4 production and the effect on the milk fatty acid profile of cows depending on strain type and diet formulation [11]. Feeding oregano oil to sheep did not change rumen pH, but promoted the growth of certain rumen microbiota, and low doses of oregano oil had a positive effect on rumen microbes, while high doses harmed rumen microbes [12]. In a dextran sodium sulfate-induced mouse model, essential oil of Zanthoxylum bungeanum pericarp alters the level of colonic microbial composition and has a positive effect on ulcerative colitis [13]. The above studies suggest that herbs, probiotics, and essential oils are some of the strategies currently used in animal production to promote growth and improve immunity. Although these studies have yielded fruitful results, there are some shortcomings. The health status of the animal and the increase in productivity are the result of the collaboration of multiple systems in the organism and are not determined by a few single systems. Therefore, in this study, the effects of EOZB on rumen enzyme activity, rumen microbial composition, and its metabolites in STH lambs were analyzed by a combination of kit method, 16s rRNA high-throughput sequencing, and LC/GC-MS metabolomics, aiming to provide new insights into the mechanism of action of EOZB in ruminants.

Materials and methods

Ethics statement

All studies involving animals were carried out under the regulations for the Administration of Affairs Concerning Experimental Animal (Ministry of Science and Technology, China; revise in June 2004), and sample collection protocols were approved by the Experimental Animal Ethics Committee of Gansu Agricultural University (Approval No. GSAU-Eth-AST-2021-026). Written informed consent was obtained from the owners for the participation of their animals in this study.

Experimental design and sampling

Twenty STH lambs (male lambs, 3-month-old, initial weight = 23.57 ± 4.61 kg, P>0.05) were obtained from a farm in Dingxi City (Gansu Province, China). The experimental lambs were housed in individual pens that were disinfected and cleaned regularly. The lambs were randomly divided into four groups (n = 5/group) and provided the same diets (Table 1). The BD (quality = 1 kg) was provided for each lamb every day. ALW group was fed a BD; BLW group: BD+ EOZB 5 ml/kg; CLW group: BD+ EOZB 10 ml/kg; DLW group: BD+ EOZB 15 ml/kg. According to different trial groups, different doses of EOZB were administered daily. The experiment was performed for a total of 52 days, the lambs in each group were stunned (head electric shock) and then sacrificed (performed by professional butchers) by exsanguination of the jugular vein after the end of the trial. Rumen content (solid-liquid mixing) was collected into 1.5 ml sterile polypropylene tubes, immediately frozen in liquid nitrogen at -80 °C, and stored for further analysis of the microbiome and metabolome. At the same time, rumen content was collected in sterilized cryotubes and stored at -20 °C for the determination of rumen digestive enzyme activity.

Table 1. Basal diet composition and nutritional level (DM basis).

Dietary composition %
Wheat straw 50
Concentrate pellets 50
Nutritional levels
CP 19.87
EE 5.06
Ash 16.85
Ga 1.32
P 0.60
NDF 113.50
ADF 61.89

Note: The concentrated pellet was purchased from the manufacturer (5, 10 and 15 ml/kg of EOZB were added), and nutrient levels were determined in the laboratory.

Rumen digestive enzyme activity

The activity of eight rumen digestive enzymes (cellulase, neutral xylanase, pectinase, lysozyme, neutral protease, lipase, α-amylase, and pepsin) was determined. Each sample underwent a homogenization (0.9% normal saline) pretreatment, with 1 g of frozen rumen content being accurately weighed and added to the homogenization medium at a mass-volume ratio of 1:9 (g/mL). Mixing took place in an ice water bath to make a 10% homogenate. The homogenate was then centrifuged (4000 rpm for 10 min at room temperature), the supernatant was collected, and the target enzyme activity was determined according to the instructions of the appropriate kit. Total protein was measured by the total protein detection kit (Nanjing Jiancheng Bioengineering Institute, Jiangsu, China). The activities of cellulase, neutral xylanase, pectinase, lysozyme, neutral protease, lipase, α-amylase, and pepsin were measured by the cellulase detection kit (Nanjing Jiancheng Bioengineering Institute, Jiangsu, China), the neutral xylanase detection kit (Beijing Solarbio Science & Technology Co., Ltd, Beijing, China), the pectinase detection kit (Nanjing Jiancheng Bioengineering Institute, Jiangsu, China), the lysozyme detection kit (Nanjing Jiancheng Bioengineering Institute, Jiangsu, China), the neutral protease detection kit (Beijing Solarbio Science & Technology Co., Ltd, Beijing, China), the lipase, α-amylase detection kit (Nanjing Jiancheng Bioengineering Institute, Jiangsu, China), and the pepsin detection kit (Nanjing Jiancheng Bioengineering Institute, Jiangsu, China).

DNA extraction and high-throughput sequencing

Total DNA was extracted from ruminal samples using the E.Z.N.A.® Stool DNA Kit (Omega Bio-Tek, Norcross, GA, USA) according to the manufacturer’s protocol. The V4-V5 region of the bacteria 16S ribosomal RNA gene was amplified by PCR (95 °C for 5 min, followed by 30 cycles at 95 °C for the 30 s, 55 °C for 30 s, and 72 °C for 45 s, and a final extension at 72 °C for 5 min), using primers 515F (5’-GTGCCAGCMGCCGCGG-3’) and 907R (5’-CCGTCAATTCMTTTRAGTTT-3’), where the barcode was a six-base sequence unique to each sample. PCR reactions were performed in 30 μl of the mixture containing 15 μl of 2 × Phanta Master Mix, 1 μl of each primer (10 μM), and 20 ng of template DNA. Amplicons were extracted from 2% agarose gels and purified using the AxyPrep DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, USA), according to the manufacturer’s instructions. Purified PCR products were quantified by Qubit®3.0 (Life Invitrogen, CA, USA) and every 20 amplicons whose barcodes were different were mixed equally. The pooled DNA product was used to construct the Illumina pair-end library following Illumina’s genomic DNA library preparation procedure. The amplicon library was then paired-end sequenced (2×250) on an Illumina Novaseq 6000 platform (Nanjing GenePioneer Co. Ltd, Nanjing, China) according to the standard protocol.

Raw data returned by the Illumina HiSeq sequencing platform were filtered using the software packages Pandaseq [14], PRINSEQ [15], and Vsearch [16] (v2.15.0_linux_x86_64) to remove chimeras and obtain optimized sequences (tags). Operational taxonomic units (OTUs) were clustered using Vsearch (v.2.15.0_linux_x86_64), and the clustering similarity threshold was 97%. Using the self-developed perl program to random rarefaction the data of each sample (the number of rarefaction is the minimum number of sample sequences). QIIME (v.1.9.1) was used to select the most abundant sequence from each OTU as the representative sequence, and then the Uclust method was used to compare the representative sequence to the Silva rRNA database (release_132) and classify the OTU species. Based on the abundance and annotation information of OTUs, the proportion of sequences in each sample at different taxonomic levels was counted to assess species abundance and species diversity of the samples. Alpha diversity was assessed by Observed species, Chao1, Shannon, and Simpson indexes [17], and data were plotted as a rarefaction curve. Beta diversity analysis was used to compare differences in species diversity (microbial composition and structure) between different samples. Using PICRUSTt2 [18] for functional gene analysis (The OTU abundance table was standardized, and the KO information and COG family information corresponding to OTUs were obtained by mapping each OTU’s corresponding relative, aligning to the KEGG and COG databases), which predicts the gene function of the sample and calculate the functional gene abundance.

LC-MS analysis

Metabolomics analysis was performed on a dual detection platform. First, perform metabolomics analysis based on an LC-MS system combined quadrupole Orbitrap mass spectrometer (Q Exactive Orbitrap, Thermo Fisher Scientific, USA.) [19]. STH lamb rumen contents that had been preserved at -80°C (20 cases; 4 groups with 5 cases in each group) were used to perform LC-MS metabolomic analysis. A 50 mg sample was weighed and mixed with 1000 μl of extraction solution (methanol: acetonitrile: water = 2:2:1 (V/V), containing isotope-labeled internal standard mixture); grinding took place at 35 Hz for 4 min, followed by sonication in an ice water bath for 5 min (repeated 3 times), then to -40°C let stand for 1 h. The samples were centrifuged at 4 °C, 12 000 RPM [centrifugal force 13800 (×g), radius 8.6 cm] for 15 min. The supernatant was taken up in an injection vial for machine detection, all samples with an equal amount of supernatant were mixed into a QC sample for machine detection.

A Vanquish ultra-high performance liquid chromatograph (Thermo Fisher Scientific) was used to separate the target compounds through a Waters ACQUITY UPLC BEH Amide (2.1 mm × 100 mm, 1.7 μm) liquid chromatographic column. The A phase of the liquid chromatography was the water phase, containing 25 mmol/l ammonium acetate and 25 mmol/l ammonia water, and the B phase was acetonitrile. A sample pan temperature of 4°Cand an injection volume of 3 ml was used. A Thermo Q Exactive HFX mass spectrometer performed primary and secondary mass spectrometric data acquisition under the control of Xcalibur software (v.4.0.27, Thermo). The detailed parameters were as follows: sheath gas flow rate: 30 ARB, aux gas flow rate: 25 ARB, capillary temperature: 350 °C, full MS resolution: 60 000, MS/MS resolution: 7500, collaboration energy: 10/30/60 in NCE mode, spray Voltage: 3.6 kV (positive) or—3.2 kV (negative).

After the original data was converted into mzXML format by ProteoWizard software, a self-written R program package (the kernel was XCMS) was used for peak identification, peak extraction, peak alignment, and integration, and then it was matched with the second mass spectrum database for substance annotation and algorithm scoring. The Cutoff value was set to 0.3. After data quality control and data preprocessing of metabolomics raw data, differential metabolite screening and identification, KEGG annotation of differential metabolites, KEGG pathway type analysis of differential metabolites, and KEGG pathway enrichment analysis of differential metabolites were carried out.

GC-TOF-MS analysis

Metabolomics analysis was performed on a dual detection platform. Secondly, perform metabolomics analysis based on a GC-MS gas chromatography-time-of-flight mass spectrometer equipped with an Agilent DB-5MS capillary column (J&W Scientific, Folsom, CA, USA). STH lamb rumen content, preserved at -80°C (20 cases;4 groups with 5 cases in each group) was used to perform GC-TOF-MS metabolomic analysis. Samples of 50 ± 1 mg were taken in a 2 ml EP tube and 1000 μl pre-cooled extraction solution (methanol acetonitrile-water volume ratio = 2:2:1) containing 5 μl ribitol. The mixture was vortexed for 30 s, steel beads were added, 35 Hz grinding took place for 4 min, followed by sonication in an ice water bath for 5 min (repeated 3 times), then to -40°C let stand for 1 h. The samples were centrifuged at 4 °C, 12 000 RPM [centrifugal force 13800 (×g), radius 8.6 cm] for 15 min and 400 μl of supernatant was carefully pipetted into a 1.5 ml EP tube. Samples of 50 μl were taken and mixed into a QC sample. The extract was dried in a vacuum concentrator and 30 μl of methoxyamine salt reagent (methoxyamine hydrochloride, dissolved in pyridine 20 mg/ml) was added to the dried metabolites. After mixing gently, the mixture was placed in an oven and incubated at 80°C for 30 min. Aliquots of 40 μl BSTFA (containing 1% TMCS, v/v) were added to each sample, the mixture was incubated at 70°C for 1.5 h, cooled down to room temperature, 5 μl of FAMEs (dissolved in chloroform) were added to the mixed sample, and random order testing was conducted.

GC-TOF-MS analysis was performed using an Agilent 7890 gas chromatograph coupled with a time-of-flight mass spectrometer. The system utilized a DB-5MS capillary column. Aliquots (1 μl) of the sample were injected in splitless mode. Helium was used as the carrier gas, the front inlet purge flow was 3 ml/min, and the gas flow rate through the column was 1 ml/min. The initial temperature was kept at 50°C for 1 min, then raised to 310°C at a rate of 10°C/min, then kept for 8 min at 310°C. The injection, transfer line, and ion source temperatures were 280°C, 280°C, and 250°C, respectively. The energy was -70 eV in electron impact mode. The mass spectrometry data were acquired in full-scan mode with an m/z range of 50–500 at a rate of 12.5 spectra per second after a solvent delay of 6.27 min.

Mass spectrometric data were analyzed using ChromaTOF software (v.4.3x, LECO) for peak extraction, baseline correction, deconvolution, peak integration, and peak alignment [20]. In the qualitative work of substances, the LECO-Fiehn Rtx5 database was used, including mass spectrometry matching and retention time index matching. Finally, peaks with a call rate below 50% or RSD >30% in QC samples were removed [21]. After data quality control and data preprocessing of metabolomics raw data, differential metabolite screening and identification, KEGG annotation of differential metabolites, KEGG pathway type analysis of differential metabolites, and KEGG pathway enrichment analysis of differential metabolites were carried out.

Statistical data analysis

SPSS software (v.21.0, SPSS Inc.) was used for one-way analysis of variance to analyze the relative abundance of rumen bacteria and the activity of digestive enzymes in the rumen at different levels, multiple-comparisons between groups were performed using Duncan’s method, P < 0.05 indicated a significant difference. R (v.3.6.2) was used to perform rank-sum test analysis on different indexes of rumen microbial Alpha diversity; P<0.05 indicated a significant difference. Spearman correlation test was used to analyze the correlation between rumen microbes with rumen metabolites and rumen enzyme activity. Metabolomics data conduct univariate statistical analysis (including Student’s t-test) and multivariate statistical analysis (including principal component analysis (PCA) and orthogonal partial least squares (OPLS-DA) analysis).

Results

Rumen enzyme activities

The effect of EOZB on ruminal enzyme activity of STH lambs is shown in Table 2. The activity of the digestive enzymes measured tended to increase and then decrease with increasing doses of EOZB. Among them, EOZB 10 ml/kg (CLW group) significantly increased the activity of rumen Pectase and Lipase (P<0.05).

Table 2. Effect of EOZB on enzyme activity in the rumen content of STH lambs (U/mg protein).

Digestive enzyme ALW BLW CLW DLW P-Value
Cellulase 1351.01±38.82 1293.82±59.35 1402.91±34.68 1029.36±22.97 0.306
Neutral xylanase 688647.87±928.28 806880.53±635.70 1058229.64±566.41 563015.84±927.08 0.099
Pectase 1.36±0.02c 1.74±0.01b 1.98±0.03a 1.35±0.02c <0.001
Lysozyme 798.71±66.63 857.42±75.61 970.15±81.95 645.66±93.36 0.109
neutral protease 48287.97±212.43 55163.29±590.40 63302.75±275.63 46436.71±198.58 0.329
Lipase 466005.35±33.54c 552713.45±45.77b 555095.54±51.29a 377892.87±41.54d <0.001
Amylase 0.87±0.05 0.98±0.09 1.08±0.03 0.73±0.07 0.052
Pepsin 103.04±3.14 118.35±1.51 119.11±6.81 90.02±5.70 0.195

Note: Different lowercase letters in a row indicate significant differences (P<0.05).

Diversity of rumen microbes

A total of 2727562 tags were obtained from 20 samples in this study, and 2552906 clean tags were obtained after stitching, optimization, and quality control. According to the minimum number of detected sequences, 117434 sequences were taken from each sample for subsequent analysis (S1 Table). Clustering was performed at 0.97 similarities using Vsearch, resulting in OTU for each sample. A total of 3677 OTUs were generated, and 2940 remained after random rarefaction, and representative sequences of OTUs were selected for species annotation. There were 2600 shared OTUs in ALW, BLW, CLW, and DLW, 2829 OTUs in ALW and BLW, 2914 OTUs in ALW and CLW, and 2908 OTUs in ALW and DLW. The number of unique OTUs in the CLW group was significantly higher than that in the other groups (Fig 1A). Species accumulation curves, which are used to describe the condition of increasing species as sample size increases, are widely used to judge the adequacy of sample size and for the estimation of species richness. The curve began to flatten as the sample size reached 10, indicating adequate sample size and saturation of sequencing coverage (Fig 1B). PCoA analysis revealed significant differences in rumen microbial species between the EOZB group and the BD group (Fig 1C). Anosim analysis further showed that the differences between groups were significantly greater than within groups (Fig 1D). As shown in Table 3, the Chao1 index of EOZB 15 ml/kg (DLW group) was significantly higher (P<0.05) than the other trial groups, indicating that a certain dose of EOZB could alter the rumen microbial abundance of STH lambs. Shannon and Simpson indices were also higher in the EOZB 15 ml/kg (DLW group) than in the control group, but the difference was not significant.

Fig 1. Differences in the structure of STH rumen bacteria with the addition of EOZB.

Fig 1

(A) Analysis of OTU-Venn diagram of each experimental group with EOZB; (B) Species accumulation curves; (C, D) PCoA and Anosim analysis.

Table 3. Effect of EOZB on the index of ruminal alpha diversity in STH lambs.

Index ALW BLW CLW DLW SEM P-Value
Chao1 2415.65b 2413.15b 2411.76b 2521.18a 10.17 <0.001
Observed species 2155.60 2151.20 2131.00 2151.60 19.05 0.579
Shannon 8.24 8.26 8.25 8.27 0.04 0.851
Simpson 0.99 0.99 0.99 0.99 <0.01 0.582

Note: Different lowercase letters in a row indicate significant differences (P<0.05).

Effect of EOZB on rumen microbial composition

At the taxonomic level, the phylum level Bacteroidetes, Firmicutes, Proteobacteria, Tenericutes, Fibrobacteres, and Spirochaetes were the dominant bacteria, with their relative abundance greater than 1%. The relative abundance of Bacteroidetes and Firmicutes had the highest relative abundance in each trial group, accounting for more than 88% of rumen bacteria (Fig 2A). In addition, among the bacteria with relative abundance greater than 1% at the rumen phylum level, Tenericutes, Fibrobacteres, and Spirochaetes had the highest relative abundance in the ALW group (P<0.05); Firmicutes had the highest relative abundance in the BLW group (P<0.05); Bacteroidetes had the highest relative abundance in the CLW group (P<0.05); the highest relative abundance of Proteobacteria in the DLW group (P<0.05) (S2 Table). Genus level Prevotella_1, Rikenellaceae_RC9_gut_group, Prevotellaceae_UCG_001, Prevotellaceae_UCG_003, Christensenellaceae_R_7_group, Fibrobacter, Rumen_bacterium_YS3, Ruminococcaceae_NK4A214_group, Succiniclasticum, Treponema_2, Saccharofermentans, and Ruminococcaceae_UCG_014 were the dominant genera and their relative abundance was greater than 1% (Fig 2B).

Fig 2. Abundance of STH rumen bacteria added with EOZB at phylum and genus levels.

Fig 2

(A) Relative abundance of rumen bacteria at the phylum level; (B) Relative abundance of rumen bacteria at the genus level.

Prevotella_1 and Rikenellaceae_RC9_gut_groups had the highest relative abundance in each trial group, accounting for more than 28% of the total rumen bacteria. In addition, among the bacteria with relative abundance greater than 1% at the rumen genus level, the ALW group Prevotella_1, Rumen_bacterium_YS3, Succiniclasticum had the highest relative abundance (P<0.05); the BLW group Prevotellaceae_UCG_003, the Christensenellaceae_R_7_group, Saccharofermentans showed the highest relative abundance, but only Christensenellaceae_R_7_group showed a significant level of relative abundance (P<0.05); CLW group Rikenellaceae_RC9_gut_group, Ruminococcaceae_NK4A214_group, Treponema_2, had the highest relative abundance (P<0.05); DLW group Prevotellaceae_UCG_001, Fibrobacter had the highest relative abundance, but the difference was not significant (S2 Table). LEfSe analysis of samples between groups showed that the addition of EOZB created a total of 21 differential biomarkers (LDA score >4) (Fig 3), which is consistent with ANOVA analysis. Overall, the addition of EOZB caused significant differences.

Fig 3. Between-group biomarkers.

Fig 3

LDA value distribution histogram.

Gene function prediction

Using PICRUSt2 to predict gene function, 38 KEGG gene families and 24 COG gene families were identified in 16S rRNA gene sequencing data. Among them, five KEGG gene families showed significant differences in the EOZB groups (Fig 4), and three COG gene families showed significant differences (Fig 5). The addition of low-dose (BLW) EOZB in the KEGG gene family significantly enhanced the Circulation system (P = 0.009) and Infectious diseases: viral (P = 0.019) related genes. The addition of medium-dose (CLW) EOZB significantly enhanced Infectious diseases: viral (P = 0.034) associated genes. The addition of high-dose (DLW) EOZB significantly decreased Translation (P = 0.013), Replication and repair (P = 0.017), and Endocrine metabolic diseases (P = 0.032) related genes. In the COG gene family, adding low-dose (BLW) EOZB significantly enhanced Cytoskeleton (P = 0.037) related genes. The addition of high-dose (DLW) EOZB significantly enhanced Lipid transport and metabolism (P = 0.038) and Extracellular structures (P = 0.043) related genes.

Fig 4. KEGG functional pathways.

Fig 4

Differences in KEGG functional pathways between groups.

Fig 5. COG functional pathways.

Fig 5

Differences in COG functional pathways between groups.

Rumen metabolites and metabolic pathways

To further explore the effect of adding EOZB on rumen microbes and their metabolites in the studied STH lambs, the concentration of rumen metabolites in the four groups was analyzed by a combined method of LC-MS and GC-MS. A total of 1073 metabolites were found (S3 Table). These metabolites included amino acids, organic acids, lipids, nucleotides, etc. which are involved in many rumen biochemical processes in sheep. The PCA score chart was derived from the LC/GS-MS metabolic spectrum. From the results of the PCA score chart, all samples were within the 95% confidence interval; this data is worthy of further study (Fig 6A–6C). From the scatter plot of the OPLS-DA model, the sample distinction between groups was very significant (Fig 6D–6F). In addition, the OPLS-DA’s permutation test showed that the original model did not have an over-fitting phenomenon, and the model was robust (the over-fitted models R2 and Q2 remained unchanged). Among them, the ALW group compared with BLW R2Y = 0.921, Q2Y = -0.345; ALW group compared with CLW R2Y = 0.936, Q2Y = 0.152; ALW group compared with DLW R2Y = 0.959, Q2Y = -0.012 (Fig 6G–6I). The above data demonstrated that the OPLS-DA model of this study was effective.

Fig 6.

Fig 6

(A) Scatter plot of the PCA of ALW_vs_BLW; (B) Scatter plot of the PCA of ALW_vs_CLW; (C) Scatter plot of the PCA of ALW_vs_DLW; (D) Scatter point graph of the OPLS-DA model of ALW_vs_BLW; (E) Scatter point graph of the OPLS-DA model of ALW_vs_CLW; (F) Scatter point graph of the OPLS-DA model of ALW_vs_DLW; (G) Permutation test result of the OPLS-DA model of ALW_vs_BLW; (H) Permutation test result of the OPLS-DA model of ALW_vs_CLW; (I) Permutation test result of the OPLS-DA model of ALW_vs_DLW.

The differential metabolites between groups were screened according to the criteria of VIP >1.5 (VIP: the VIP value from OPLS-DA model), P < 0.05. Among them, the ALW group had 28 different metabolites compared with BLW, including pe(20:0/14:1(9z)), prolylglycine, l-hypoglycin a, kynurenic acid, batatasin iii, n-lactoyl ethanolamine, beta-alanine, nicotine imine, 4-amino-2-methylenebutanoic acid, aspartyl-valine, lysope(0:0/18:3(6z,9z,12z)), asymmetric dimethylarginine, benzaldehyde, levan, pe(p-18:1 (11z)/14:1(9z)), 2,5-dihydro-2,4-dimethyloxazole, Indole, 2-pyridylacetic acid, l-allothreonine, pc(18:3(6z,9z,12z)/15: 0), 2-piperidinone, histidinyl-proline, pc(22:6(4z,7z,10z,13z,16z,19z)/16:0), artomunoxanthentrione epoxide, n-acetyl-d-galactosamine 1, lysopc(20: 3(5z,8z,11z)), trans-3,3’,4’,5,5’,7-hexahydroxyflavanone, and valyl-lysine. Compared with CLW, the ALW group had seven different metabolites, including methylsuccinic acid, pe(22:5(4z,7z,10z,13z,16z)/14:0), diethanolamine, pe(p-18:1(9z)/18:1(9z)), glutaconic acid, pc(18:3(6z,9z,12z)/15:0), and 2-piperidinone. Compared with DLW, the ALW group had 23 different metabolites, including pe(20:0/14:1(9z)), as 1–1, pc(18:1(11z)/p-16:0), hexacosanoyl carnitine, beta-alanine, pe(p-18:1(11z)/16:0), metenamine, asymmetric dimethylarginine, picraquassioside a, pe(p-18:1(11z)/14:1(9z)), pe(p-18:1(9z)/18:1(9z)), 2-propylfuran, n-cyclohexylformamide 1, pc(18:3(6z,9z,12z)/18:0), indole, muricatacin, digitoxose 1, pc(15:0/p-18:1(9z)), pc(18:3(6z,9z,12z)/15:0), 2-piperidinone, capryloylglycine, artomunoxanthentrione epoxide, trans-3, and 3’,4’,5,5’,7-hexahydroxyflavanone (S4 Table). Further enrichment analysis showed that adding EOZB to the diet significantly changed Glycerophospholipid metabolism, Choline metabolism in cancer, Retrograde endocannabinoid signaling, Benzoxazinoid biosynthesis, and Protein digestion and absorption (Fig 7A–7C).

Fig 7. Metabolic pathways.

Fig 7

Enrichment analysis of metabolic pathways.

Correlation analysis

Spearman correlation coefficient analysis (r>0.5 or r<- 0.5, P<0.05) was performed using VIP>1.5 (VIP: the VIP value from OPLS-DA model) P<0.05 for differential metabolites with significantly different populations in abundance at the genus level (P<0.05). As shown in the Fig 8, Prevotella_1 was significantly and positively correlated with pe(20:0/14:1(9z)), 2-piperidinone, indole, 4-amino-2-methylenebutanoic acid, pc(18:3(6z,9z,12z)/15:0), muricatacin, beta-alanine, pc(16:1(9z)/p-18:0), trans-3,3’,4’,5,5’,7-hexahydroxyflavanone, aspartyl-valine, lysope(0:0/20:4(5z,8z,11z,14z)), artomunoxanthentrione epoxide, lysope(0:0/18:3(6z,9z,12z)), pe(p-18:1(9z)/15:0), pc(22:6(4z,7z,10z,13z,16z,19z)/16:0), lysopc(20:3(5z,8z,11z)) (r>0.5,P<0.05). Rikenellaceae_RC9_gut_group was significantly and positively correlated with pe(20:0/14:1(9z)), 4-amino-2-methylenebutanoic acid, lysope(18:1(9z)/0:0), pc(16:1(9z)/p-18:0), batatasin iii, aspartyl-valine, lysope(0:0/18:3(6z,9z,12z)), pe(p-18:1(9z)/15:0), pectinase, lipase (r>0.5,P<0.05). Rumen_bacterium_YS3 was significantly and positively correlated with pe(20:0/14:1(9z)), 2-piperidinone, indole, 4-amino-2-methylenebutanoic acid, pc(18:3(6z,9z,12z)/15:0), muricatacin, beta-alanine, pc(16:1(9z)/p-18:0), 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine, trans-3,3’,4’,5,5’,7-hexahydroxyflavanone, aspartyl-valine, lysope(0:0/20:4(5z,8z,11z,14z)), artomunoxanthentrione epoxide, prolyl-threonine, lysope(0:0/18:3(6z,9z,12z)), pe(p-18:1(9z)/15:0), pc(22:6(4z,7z,10z,13z,16z,19z)/16:0), lysopc(20:3(5z,8z,11z)) (r>0.5,P<0.05) and significantly negatively correlated with pectinase, lipase (r<0.5,P<0.05). Fibrobacter was significantly and positively correlated with 2,5-dihydro-2,4-dimethyloxazole, 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine, lysope(18:1(9z)/0:0) (r>0.5,P<0.05) and significantly negatively correlated with pectinase, lipase (r<0.5,P<0.05). Christensenellaceae_R_7_group was significantly and negatively correlated with pe(20:0/14:1(9z)), 2-piperidinone, indole, 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine, lysope(0:0/20:4(5z,8z,11z,14z)), artomunoxanthentrione epoxide, prolyl-threonine (r<0.5,P<0.05) and positively correlated with pectinase, lipase (r>0.5,P<0.05). Treponema_2 was significantly and negatively correlated with 2-piperidinone, pc(18:3(6z,9z,12z)/15:0), 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine, pc(22:6(4z,7z,10z,13z,16z,19z)/16:0) (r<0.5,P<0.05) and significantly positively correlated with batatasin iii, pectinase, lipase (r>0.5,P<0.05). Ruminococcaceae_NK4A214_group was significantly and positively correlated with pectinase, lipase batatasin iii (r>0.5,P<0.05). Succiniclasticum was significantly and positively correlated with pe(20:0/14:1(9z)), 2-piperidinone, indole, 4-amino-2-methylenebutanoic acid, pc(18:3(6z,9z,12z)/15:0), muricatacin, hydroxycotinine, beta-alanine, pc(16:1(9z)/p-18:0), trans-3,3’,4’,5,5’,7-hexahydroxyflavanone, aspartyl-valine, lysope(0:0/20:4(5z,8z,11z,14z)), artomunoxanthentrione epoxide, lysope(0:0/18:3(6z,9z,12z)), pe(p-18:1(9z)/15:0), pc(22:6(4z,7z,10z,13z,16z,19z)/16:0) (r>0.5,P<0.05) (Fig 8).

Fig 8. The connection between microorganisms and metabolites and enzymatic.

Fig 8

Heatmap of correlations between microorganisms and metabolites and enzymatic activities. *P < 0.05, **P < 0.01, ***P < 0.001.

Discussion

Z. bungeanum is a plant belonging to the genus Zanthoxylum of the Rutaceae family. It is currently widely distributed in most parts of China and some Southeast Asian countries. Z. bungeanum is rich in flavonoids, including rutin, quercetin, foeniculin, hyperin, and isoquercitrin [22]. Owing to its unique flavor and medicinal value, Z. bungeanum is now widely used as a flavoring agent and traditional Chinese herbal medicine [23] as it has a variety of biological and pharmacological activities, including anti-inflammatory [24], antioxidant [25], and antibacterial properties [26]. EOZB is a thick paste-like fluid with a natural spicy flavor extracted from the husk of the plant and has a similar medicinal value to the whole plant. However, there are limited reports of its application in ruminants. In this study, STH lambs were used as experimental animals, and the effects of EOZB were studied from the perspective of rumen digestive enzyme activity, the microbiome, and metabolomics.

A large number of bacteria, fungi, archaea, and protozoa inhabit the rumen, which together constitutes a complex rumen micro-ecosystem [27]. These microbiota produce various digestive enzymes and play an important role in digestion. The activity of digestive enzymes mainly depends on the type and number of rumen microbial populations and is closely related to their metabolism [24]. Pectin is widely present in plant cell walls where it is used for adhesion and support [28]. Pectin can be degraded by pectinase, and the small molecules produced can be used by ruminants [29]. Many bacteria can produce lipase, which can hydrolyze fatty acids, especially long-chain fatty acids [30]. Our research results show that adding a medium dose of EOZB (10 ml/kg) significantly increased the activities of pectinase (P<0.05) and lipase (P<0.05) in the rumen of STH lambs. This may imply that appropriate doses of EOZB help ruminants to utilize plant-based feeds and enhance lipid metabolism.

The main function of members of the phylum Bacteroidetes in the host is to degrade carbohydrates and proteins [31, 32]. The main function of members of the phylum Firmicutes in the host is to enhance energy metabolism [33]. A high ratio of F/B (Firmicutes/Bacteroidetes) can help the host to efficiently absorb energy substances and maintain metabolic balance [34, 35]. In this study, Bacteroidetes, Firmicutes were the dominant group at the level of Phylum. Bacteroidetes significantly increased (P<0.05) at the dose of EOZB (10 ml/kg), Firmicutes significantly increased (P<0.05) at the dose of EOZB (5 ml/kg) and F/B (Firmicutes/Bacteroidetes) significantly increased (P<0.05) at the dose of EOZB (5 ml/kg). (P<0.05). This may imply that appropriate doses of EOZB help ruminants digest and absorb carbohydrates and proteins, and enhance energy metabolism. In addition, it has been shown that Tenericutes is the most prevalent bacterial phylum in diseased crabs [36]. Spirochaetes is a highly prevalent pathogenic agent [37]. EOZB significantly reduced the relative abundance of Tenericutes and Spirochaetes (P<0.05). This may imply that EOZB has certain antimicrobial properties that help the animal organism to resist pathogenic bacteria.

Prevotella has properties that degrade plant polysaccharides and promote inflammatory processes [38, 39]. At the genus level, the dominant genera in the STH lambs rumen were Prevotella_1 and Rikenellaceae_RC9_gut_group. We found that the relative abundance of Prevotella_1 was significantly lower (P<0.05) in the trial group supplemented with EOZB, which may imply that EOZB has anti-inflammatory properties. The specific function of the Rikenellaceae_RC9_gut_group is currently unknown, but the Rikenellaceae_RC9_gut_group is closely related to members of the genus Alistipes [40], and Alistipes has the effect of degrading plant-based polysaccharides [41, 42]. Therefore, the Rikenellaceae_RC9_gut_group may be associated with the degradation of phytogenic polysaccharides. In addition, Rikenellaceae resists the development of colonic inflammation and can limit the inflammatory process by stimulating T-cell differentiation [43]. We found that the relative abundance of Rikenellaceae_RC9_gut_group was significantly increased (P<0.05) at the dose of EOZB (10 ml/kg), which may suggest that EOZB has the function of helping ruminants to utilize plant-based carbohydrates and inhibit inflammatory processes. Cellulolytic bacteria are an important group of bacteria that degrade cellulose in the rumen and play a key role in the production of VFA [44, 45]. Among these Cellulolytic bacteria, Fibrobacter increased significantly (P<0.05) at the dose of EOZB (15 ml/kg) and the Ruminococcaceae_NK4A214_group increased significantly (P<0.05) at the dose of EOZB (10 ml/kg). This may imply that EOZB tools have a positive effect on the utilization of cellulose-based nutrients by ruminants.

We used PICRUSt2 to predict rumen microbial gene function and to reveal the influence of EOZB on rumen microbial function. The prediction of the KEGG gene family indicated that the addition of EOZB could significantly enhance functions related to the Circulatory system (P = 0.009). EOZB (5 ml/kg and 10 ml/kg) significantly enhance the functions related to Infectious diseases: Viral. (P = 0.019, P = 0.034). The prediction of the COG gene family indicated that adding EOZB could significantly enhance functions related to Lipid transport and metabolism (P = 0.038). The enhancement of these functions in STH lambs may be related to the medicinal properties and therapeutic dose of EOZB, but there are currently no relevant reports of such findings.

Studies have shown that metabolite changes, microbial changes, and their connections are the main risk factors for abnormal tissue function and diseases, such as cancer [46], metabolic diseases [47], cardiovascular diseases [48], insulin resistance [49], and obesity [50]. Changes in gastrointestinal microbiota can directly alter their metabolic capacity and then affect local gastrointestinal function. For example, the fecal microbiome and metabolome of patients with systemic lupus erythematosus are simultaneously disordered [51]. The results of the current study showed that EOZB changed rumen protein digestion and absorption and glycerophospholipid metabolism in STH lambs. The essential amino acid tryptophan (TRP), as a precursor of protein synthesis, serotonin synthesis, and the kynurenine (KYN) pathway, plays a vital role in different physiological processes in the body and is closely related to the immune system and nervous system. The vast majority of available tryptophan is metabolized through the KYN pathway [52]. This pathway can promote the release of inflammatory cytokines IFN-γ and IL-6. Furthermore, KYN can be converted into kynurenic acid (KA) or nicotinamide adenine dinucleotide+ (NAD+) under the action of KYN transferase [53]. The immunomodulatory effect of the KYN pathway is related to the conversion level of KYN and the expression level of KA. Both KYN and KA can promote the differentiation of T cell subsets into regulatory T cells [54]. KYN molecules can also be decomposed into nicotinamide adenine dinucleotide+ (NAD+) and quinolinic acid (QA) through the KYN pathway. In the central nervous system, QA mediates neuronal excitotoxicity, while kynurenic acid provides neuronal protection. However, only TRP and KYN can cross the blood-brain barrier, while QA and KA cannot [55]. Therefore, the kynurenine pathway has the effect of regulating the immune system and nervous system, and the tryptophan-kynurenine pathway may be used to explain the brain-gut axis theory of microbiota and hosts. Interestingly, in this study, the rumen chyme of STH sheep in the EOZB group (BLW) was analyzed by metabolomics, and the expression of the differential metabolite kynurenic acid was higher than that of the control group (ALW). This may suggest that EOZB can modulate the immune system by enhancing the kynurenine pathway. It has been widely shown that phosphatidylcholine is a powerful marker of age-related membrane degeneration and low levels in plasma are positively associated with cognitive decline [5659]. The main components of phosphatidylcholine include the long-chain polyunsaturated fatty acid docosahexaenoic acid (DHA) and choline, which can predict age-related executive function decline [6063]. Interestingly, pc(18:3(6z,9z,12z)/15:0) expression in this study was significantly lower in the CLW group than in the control group (P<0.05), which may imply that low doses of EOZB can inhibit the nervous system and thus have an analgesic pharmacological function.

The host gastrointestinal microbiota can help the host digest and absorb various nutrients, and at the same time produce various small molecules that affect the host’s physiological health, immunity, metabolism, growth, development, etc. [64]. It has been shown that the microbiome and metabolome of colorectal cancer patients are simultaneously disturbed [6567]. Thus, there is a link between the microbiota and the small molecules it produces. It has been shown that Prevotella has properties that promote the inflammatory process [68]. Similarly, 2_piperidinone has biological activities in organisms that promote angiogenesis and promote the development of inflammation [69]. We found that Prevotella_1 was significantly and positively correlated with 2_piperidinone (r = 0.778, P<0.001). Moreover, the abundance of Prevotella_1 and the expression of 2_piperidinone were both significantly lower in the trial group supplemented with EOZB than in the control group. This further confirms that EOZB has anti-inflammatory properties. It has been reported that the relative abundance of Christensenellaceae is negatively correlated with body weight [70]. The tryptophan kynurenine pathway promotes the release of inflammatory cytokines, which in turn promotes the inflammatory process [71]. And indole is one of the end products of the tryptophan kynurenine pathway [72]. We found that Christensenellaceae_R_7_group was significantly negatively correlated with indole (r = -0.492,P<0.001). Moreover, Christensenellaceae_R_7_group abundance was significantly increased (P<0.05) at EOZB (5 ml/kg) dose, while indole content was significantly decreased (P<0.05) at EOZB (5 ml/kg and 15 ml/kg) doses. This may imply that EOZB has anti-inflammatory properties. Many digestive enzymes in the rumen of ruminants are provided by microbiota, such as cellulases, amylases, etc. [73]. This suggests a link between the rumen microbiota and digestive enzymes. We found that Christensenellaceae_R_7_group was significantly positively correlated with lipase (r = 0.694, P<0.001). This may imply that EOZB can alter the activity of certain enzymes by changing the abundance of rumen microbiota, which in turn helps ruminants digest and absorb nutrients.

Conclusions

In summary, the addition of specific doses of EOZB to the diet affected rumen enzyme activity, microbiome, metabolome, and the correlation between microbiota with metabolite and enzyme activities in STH lambs. The interactions between certain metabolites and enzyme activity with microbiota composition in the rumen of STH lambs could better explain their function, and the correlations identified could reveal which physiological processes EOZB regulates in STH lambs and provide new insights for similar studies in the future.

Supporting information

S1 Table. Sample sequencing data statistics.

(DOCX)

S2 Table. Bacterial abundance at the phylum and genus level.

(XLSX)

S3 Table. All differential metabolites.

(XLSX)

S4 Table. Differential metabolites between groups.

(XLSX)

Acknowledgments

We thank the staff at Sen Wuzhu Field and Pasture Farming Cooperative for helping to feed the test animals! We also thank the Gansu Agriculture University and the Gansu Academy of Agricultural Sciences for their help in collecting samples!

Data Availability

A AVAILABILITY STATEMENT Metabolome raw sequence data were uploaded to the MetaboLights database and are available through accession number MTBLS3683. Microbiome raw sequence data were uploaded to the National Center for Biotechnology Information (NCBI) database and are available through accession number SRR16774443- SRR16774622.

Funding Statement

We thank for the financial support: No. 1760683; No.18YF1NA091; No. 18JR2RA032; The funder, Cailian Wang, played an important role in the study design design. The funder, Guoshun Chen, played an important role in the decision to publish.

References

  • 1.Lloyd-Price J, Mahurkar A, Ahnavard GR, Rabtree JC, Rvis JO, Hall ABR, et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature. 2017;550(7674):61–66. doi: 10.1038/nature23889 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Gentile CL, Weir TL. The gut microbiota at the intersection of diet and human health. Science. 2018;362(6416):776–780. doi: 10.1126/science.aau5812 [DOI] [PubMed] [Google Scholar]
  • 3.Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano G, Gasbarrini A, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019;7(1):14. doi: 10.3390/microorganisms7010014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al. T-reg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500(7461):232–236. doi: 10.1038/nature12331 [DOI] [PubMed] [Google Scholar]
  • 5.Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474(7351):298–306. doi: 10.1038/nature10208 [DOI] [PubMed] [Google Scholar]
  • 6.Benchaar C, Calsamiglia S, Chaves AV, Fraser GR, Colombatto D, Mcallister TA, et al. A review of plant-derived essential oils in ruminant nutrition and production. Animal Feed Science & Technology. 2008;145(1–4):209–228. doi: 10.1016/j.anifeedsci.2007.04.014 [DOI] [Google Scholar]
  • 7.Wallace RJ. Antimicrobial properties of plant secondary metabolites. The Proceedings of the Nutrition Society. 2004;63(4):621–629. doi: 10.1079/pns2004393 [DOI] [PubMed] [Google Scholar]
  • 8.Patra AK, Yu ZT. Effects of Essential Oils on Methane Production and Fermentation by, and Abundance and Diversity of, Rumen Microbial Populations. Appl Environ Microbiol. 2012;78(12):4271–4280. doi: 10.1128/AEM.00309-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Schrader SM, Botella H, Jansen R, Ehrt S, Rhee K, Nathan C, et al. Multiform antimicrobial resistance from a metabolic mutation. Sci Adv. 2021;7(35):17. doi: 10.1126/sciadv.abh2037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Abdallah A, Zhang P, Abubakari AH, Elemba E, Zhong QZ, Sun ZW. Reclamation of Astragalus By-Product through Dietary Inclusion in Ruminant Diets: Effects on Growth Performance, Nutrient Digestibility, Rumen Fermentation, Blood Biochemical Parameters, and Humoral Immune Response in Sheep. Evid-based Complement Altern Med. 2019;2019:8. doi: 10.1155/2019/8530961 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Philippeau C, Lettat A, Martin C, Silberberg M, Morgavi DP, Ferlay A, et al. Effects of bacterial direct-fed microbials on ruminal characteristics, methane emission, and milk fatty acid composition in cows fed high- or low-starch diets. J Dairy Sci. 2017;100(4):2637–2650. doi: 10.3168/jds.2016-11663 [DOI] [PubMed] [Google Scholar]
  • 12.Zhou R, Wu JP, Zhang LP, Liu LS, Casper DP, Jiao T, et al. Effects of oregano essential oil on the ruminal pH and microbial population of sheep. PLoS One. 2019;14(5):14. doi: 10.1371/journal.pone.0217054 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zhang ZC, Shen P, Liu JX, Gu C, Lu XJ, Li YX, et al. In Vivo Study of the Efficacy of the Essential Oil of Zanthoxylum bungeanum Pericarp in Dextran Sulfate Sodium-Induced Murine Experimental Colitis. J Agric Food Chem. 2017;65(16):3312–3320. doi: 10.1021/acs.jafc.7b01323 [DOI] [PubMed] [Google Scholar]
  • 14.Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD. PANDAseq: PAired-eND Assembler for Illumina sequences. BMC Bioinformatics. 2012;13:7. doi: 10.1186/1471-2105-13-31 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Schmieder R, Edwards R. Quality control and preprocessing of metagenomic datasets. Bioinformatics. 2011;27(6):863–864. doi: 10.1093/bioinformatics/btr026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Rognes T, Flouri T, Nichols B, Quince C, Mahe F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016;4:22. doi: 10.7717/peerj.2584 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Li B, Zhang XX, Guo F, Wu WM, Zhang T. Characterization of tetracycline resistant bacterial community in saline activated sludge using batch stress incubation with high-throughput sequencing analysis. Water Res. 2013;47(13):4207–4216. doi: 10.1016/j.watres.2013.04.021 [DOI] [PubMed] [Google Scholar]
  • 18.Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31(9):814–821. doi: 10.1038/nbt.2676 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Gika HG, Theodoridis GA, Earll M, Wilson ID. A QC approach to the determination of day-to-day reproducibility and robustness of LC-MS methods for global metabolite profiling in metabonomics/metabolomics. Bioanalysis. 2012;4(18):2239–2247. doi: 10.4155/bio.12.212 [DOI] [PubMed] [Google Scholar]
  • 20.Zhou B, Xiao JF, Tuli L, Ressom HW. LC-MS-based metabolomics. Mol Biosyst. 2012;8(2):470–481. doi: 10.1039/c1mb05350g [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Kind T, Wohlgemuth G, Lee DY, Lu Y, Palazoglu M, Shahbaz S, et al. FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Analytical chemistry. 2009;81(24):10038–10048. doi: 10.1021/ac9019522 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6(7):1060–1083. doi: 10.1038/nprot.2011.335 [DOI] [PubMed] [Google Scholar]
  • 23.Li Y, Zeng J, Liu L, Jin X. GC-MS analysis of supercritical carbon dioxide extraction products from pericarp of Zanthoxylum bungeanum. Zhong yao cai. 2001;24(8):572–573. (in Chinese) [PubMed] [Google Scholar]
  • 24.Tezuka Y, Irikawa S, Kaneko T, Banskota AH, Nagaoka T, Xiong Q, et al. Screening of Chinese herbal drug extracts for inhibitory activity on nitric oxide production and identification of an active compound of Zanthoxylum bungeanum. Journal of ethnopharmacology. 2001, 77(2–3):209–217. doi: 10.1016/s0378-8741(01)00300-2 [DOI] [PubMed] [Google Scholar]
  • 25.Zhang Y, Wang D, Yang L, Zhou D, Zhang J. Purification and Characterization of Flavonoids from the Leaves of Zanthoxylum bungeanum and Correlation between Their Structure and Antioxidant Activity. Plos One. 2014, 9(8): e105725. doi: 10.1371/journal.pone.0105725 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Paik S-Y, Koh K-H, Beak S-M, Paek S-H, Kim J-A. The essential oils from Zanthoxylum schinifolium pericarp induce apoptosis of HepG2 human hepatoma cells through increased production of reactive oxygen species. Biological & pharmaceutical bulletin. 2005;28(5):802–807. doi: 10.1248/bpb.28.802 [DOI] [PubMed] [Google Scholar]
  • 27.Guleria S, Tiku AK, Koul A, Gupta S, Singh G, Razdan VK. Antioxidant and Antimicrobial Properties of the Essential Oil and Extracts of Zanthoxylum alatum Grown in North-Western Himalaya. Sci World J. 2013:9. doi: 10.1155/2013/790580 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Mizrahi I, Wallace RJ, Morais S. The rumen microbiome: balancing food security and environmental impacts. Nat Rev Microbiol. 2021;19(9):553–566. doi: 10.1038/s41579-021-00543-6 [DOI] [PubMed] [Google Scholar]
  • 29.Moharrery A, Das TK. Correlation between microbial enzyme activities in the rumen fluid of sheep under different treatments. Reproduction, nutrition, development. 2001;41(6):513–529. doi: 10.1051/rnd:2001106 [DOI] [PubMed] [Google Scholar]
  • 30.Giacobbe S, Pepe O, Ventorino V, Birolo L, Vinciguerra R, Faraco V. Identification and Characterisation of a Pectinolytic Enzyme from Paenibacillus xylanolyticus. BioResources. 2014;9(3):4873–4887. [Google Scholar]
  • 31.Yu P, Wang XX, Ren Q, Huang XX, Yan TT. Genome shuffling for improving the activity of alkaline pectinase in Bacillus subtilis FS105 and its molecular mechanism. World J Microbiol Biotechnol. 2019;35(11):10. doi: 10.1007/s11274-019-2749-z [DOI] [PubMed] [Google Scholar]
  • 32.Jaeger KE, Ransac S, Dijkstra BW, Colson C, van Heuvel M, Misset O. Bacterial lipases. FEMS microbiology reviews. 1994;15(1):29–63. doi: 10.1111/j.1574-6976.1994.tb00121.x [DOI] [PubMed] [Google Scholar]
  • 33.Jami E, White BA, Mizrahi I. Potential Role of the Bovine Rumen Microbiome in Modulating Milk Composition and Feed Efficiency. PLoS One. 2014;9(1):6. doi: 10.1371/journal.pone.0085423 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Nuriel-Ohayon M, Neuman H, Koren O. Microbial Changes during Pregnancy, Birth, and Infancy. Front Microbiol. 2016;7:13. doi: 10.3389/fmicb.2016.01031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kaakoush NO. Insights into the Role of Erysipelotrichaceae in the Human Host. Front Cell Infect Microbiol. 2015;5:4. doi: 10.3389/fcimb.2015.00084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Fernando SC, Purvis HT, Najar FZ, Sukharnikov LO, Krehbiel CR, Nagaraja TG, et al. Rumen Microbial Population Dynamics during Adaptation to a High-Grain Diet. Appl Environ Microbiol. 2010;76(22):7482–7490. doi: 10.1128/AEM.00388-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Murphy EF, Cotter PD, Healy S, Marques TM, O’Sullivan O, Fouhy F, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut. 2010;59(12):1635–1642. doi: 10.1136/gut.2010.215665 [DOI] [PubMed] [Google Scholar]
  • 38.Shen HS, Zang Y, Song K, Ma YC, Dai TH, Serwadda A. A Meta-Transcriptomics Survey Reveals Changes in the Microbiota of the Chinese Mitten Crab Eriocheir sinensis Infected with Hepatopancreatic Necrosis Disease. Front Microbiol. 2017;8:8. doi: 10.3389/fmicb.2017.00732 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Seshadri R, Myers GSA, Tettelin H, Eisen JA, Heidelberg JF, Dodson RJ, et al. Comparison of the genome of the oral pathogen Treponema denticola with other spirochete genomes. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(15):5646–5651. doi: 10.1073/pnas.0307639101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Ivarsson E, Roos S, Liu HY, Lindberg JE. Fermentable non-starch polysaccharides increases the abundance of Bacteroides-Prevotella-Porphyromonas in ileal microbial community of growing pigs. Animal. 2014;8(11):1777–1787. doi: 10.1017/S1751731114001827 [DOI] [PubMed] [Google Scholar]
  • 41.Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife. 2013;2:20. doi: 10.7554/eLife.01202 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Seshadri R, Leahy SC, Attwood GT, Teh KH, Lambie SC, Cookson AL, et al. Cultivation and sequencing of rumen microbiome members from the Hungate1000 Collection. Nat Biotechnol. 2018;36(4):359–367. doi: 10.1038/nbt.4110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.He B, Nohara K, Ajami NJ, Michalek RD, Tian XJ, Wong M, et al. Transmissible microbial and metabolomic remodeling by soluble dietary fiber improves metabolic homeostasis. Sci Rep. 2015;5:12. doi: 10.1038/srep10604 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Peng BY, Huang SC, Liu TT, Geng AL. Bacterial xylose isomerases from the mammal gut Bacteroidetes cluster function in Saccharomyces cerevisiae for effective xylose fermentation. Microb Cell Fact. 2015;14:14. doi: 10.1186/s12934-015-0253-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Dubin K, Callahan MK, Ren BY, Khanin R, Viale A, Ling LL, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:8. doi: 10.1038/ncomms10391 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Tajima K, Aminov RI, Nagamine T, Matsui H, Nakamura M, Benno Y. Diet-dependent shifts in the bacterial population of the rumen revealed with real-time PCR. Appl Environ Microbiol. 2001;67(6):2766–2774. doi: 10.1128/AEM.67.6.2766-2774.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Rahman NA, Parks DH, Vanwonterghem I, Morrison M, Tyson GW, Hugenholtz P. A Phylogenomic Analysis of the Bacterial Phylum Fibrobacteres. Front Microbiol. 2016;6:15. doi: 10.3389/fmicb.2015.01469 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97–101. doi: 10.1038/nature12347 [DOI] [PubMed] [Google Scholar]
  • 49.Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vila AV, Vosa U, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nature Genet. 2019;51(4):600–605. doi: 10.1038/s41588-019-0350-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Kurilshikov A, van den Munckhof ICL, Chen LM, Bonder MJ, Schraa K, Rutten JHW, et al. Gut Microbial Associations to Plasma Metabolites Linked to Cardiovascular Phenotypes and Risk A Cross-Sectional Study. CircRes. 2019;124(12):1808–1820. doi: 10.1161/circresaha.118.314642 [DOI] [PubMed] [Google Scholar]
  • 51.Wakabayashi T, Yamaguchi K, Matsui K, Sano T, Kubota T, Hashimoto T, et al. Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer’s disease. Mol Neurodegener. 2019;14:18. doi: 10.1186/s13024-019-0315-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Li Q, Liu F, Liu J, Liao ST, Zou YX. Mulberry Leaf Polyphenols and Fiber Induce Synergistic Antiobesity and Display a Modulation Effect on Gut Microbiota and Metabolites. Nutrients. 2019;11(5):19. doi: 10.3390/nu11051017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Rojo D, Hevia A, Bargiela R, Lopez P, Cuervo A, Gonzalez S, et al. Ranking the impact of human health disorders on gut metabolism: Systemic lupus erythematosus and obesity as study cases. Sci Rep. 2015;5:9. doi: 10.1038/srep08310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health. Science. 2017;357(6349):8. doi: 10.1126/science.aaf9794 [DOI] [PubMed] [Google Scholar]
  • 55.Badawy AAB. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. International journal of tryptophan research: IJTR. 2017;10:1178646917691938. doi: 10.1177/1178646917691938 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478(7368):197–203. doi: 10.1038/nature10491 [DOI] [PubMed] [Google Scholar]
  • 57.Vecsei L, Szalardy L, Fulop F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov. 2013;12(1):64–82. doi: 10.1038/nrd3793 [DOI] [PubMed] [Google Scholar]
  • 58.Mapstone M, Cheema AK, Fiandaca MS, Zhong XG, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014;20(4):415–418. doi: 10.1038/nm.3466 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Whiley L, Sen A, Heaton J, Proitsi P, Garcia-Gomez D, Leung R, et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer’s disease. Neurobiol Aging. 2014;35(2):271–278. doi: 10.1016/j.neurobiolaging.2013.08.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Norris SE, Friedrich MG, Mitchell TW, Truscott RJW, Else PL. Human prefrontal cortex phospholipids containing docosahexaenoic acid increase during normal adult aging, whereas those containing arachidonic acid decrease. Neurobiol Aging. 2015;36(4):1659–1669. doi: 10.1016/j.neurobiolaging.2015.01.002 [DOI] [PubMed] [Google Scholar]
  • 61.Wurtman R. Biomarkers in the diagnosis and management of Alzheimer’s disease. Metab-Clin Exp. 2015;64(3):S47–S50. doi: 10.1016/j.metabol.2014.10.034 [DOI] [PubMed] [Google Scholar]
  • 62.Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. The American journal of clinical nutrition. 2007;85(4):1103–1111. doi: 10.1093/ajcn/85.4.1103 [DOI] [PubMed] [Google Scholar]
  • 63.Bowman GL, Silbert LC, Howieson D, Dodge HH, Traber MG, Frei B, et al. Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology. 2012;78(4):241–249. doi: 10.1212/WNL.0b013e3182436598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Witte AV, Kerti L, Hermannstadter HM, Fiebach JB, Schreiber SJ, Schuchardt JP, et al. Long-Chain Omega-3 Fatty Acids Improve Brain Function and Structure in Older Adults. Cereb Cortex. 2014;24(11):3059–3068. doi: 10.1093/cercor/bht163 [DOI] [PubMed] [Google Scholar]
  • 65.Naber M, Hommel B, Colzato LS. Improved human visuomotor performance and pupil constriction after choline supplementation in a placebo-controlled double-blind study. Sci Rep. 2015;5:9. doi: 10.1038/srep13188 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016;165(6):1332–1345. doi: 10.1016/j.cell.2016.05.041 [DOI] [PubMed] [Google Scholar]
  • 67.Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool Microbiome and Metabolome Differences between Colorectal Cancer Patients and Healthy Adults. PLoS One. 2013;8(8):10. doi: 10.1371/journal.pone.0070803 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Wang X, Wang J, Rao B, Deng L, Huang Y, Zeng G, et al. Differences between colorectal cancer patients and healthy people in fecal microbiota and metabolites. Zhonghua wei chang wai ke za zhi. 2015;18(11):1106–1110. (in Chinese) [PubMed] [Google Scholar]
  • 69.Yang YZ, Misra BB, Liang L, Bi DX, Weng WH, Wu W, et al. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer. Theranostics. 2019;9(14):4101–4114. doi: 10.7150/thno.35186 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology. 2017;151(4):363–374. doi: 10.1111/imm.12760 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Xuan QH, Ouyang Y, Wang YF, Wu L, Li HT, Luo YY, et al. Multiplatform Metabolomics Reveals Novel Serum Metabolite Biomarkers in Diabetic Retinopathy Subjects. Adv Sci. 2020;7(22):10. doi: 10.1002/advs.202001714 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Waters JL, Ley RE. The human gut bacteria Christensenellaceae are widespread, heritable, and associated with health. BMC Biol. 2019;17(1):11. doi: 10.1186/s12915-019-0699-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Geng SJ, Cheng SS, Li Y, Wen ZS, Ma X, Jiang XM, et al. Faecal Microbiota Transplantation Reduces Susceptibility to Epithelial Injury and Modulates Tryptophan Metabolism of the Microbial Community in a Piglet Model. J Crohns Colitis. 2018;12(11):1359–1374. doi: 10.1093/ecco-jcc/jjy103 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Chun Wie Chong

29 Jun 2022

PONE-D-22-08057Effect of Zanthoxylum bungeanum essential oil on rumen enzyme activity, microbiome, and metabolites in lambsPLOS ONE

Dear Dr. Wang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 11 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Chun Wie Chong

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdfv

2. Thank you for stating the following financial disclosure: 

We thank for the financial support: No. 1760683; No.18YF1NA091; No. 18JR2RA032;

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

We thank for the financial support: No. 1760683; No.18YF1NA091; No. 18JR2RA032;

However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

We thank for the financial support: No. 1760683; No.18YF1NA091; No. 18JR2RA032;

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in your Competing Interests section:  

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now 

 This information should be included in your cover letter; we will change the online submission form on your behalf.

5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

7. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Figure 1D: ANOSIN (R na P) result are too small. Please provide a better figure.

Table 3. It would be best to standardize two digits after the dot

Line 277: How can you explain the predict genes of “Circulation system” , “Endrocne metabolic desease, Cytoesqueleton,....” if you provided the Microbial DNA sequencing?

LINE 285: The figure 4 legend needs to be improve.

Line 287: The same as before. Legend needs to better described.

Line 370: The same as before. Legend needs to better described

Reviewer #2: Line 20: The description "Subgroups:" sounds a bit strange, please check with the author.

Line 44: The numbers in the "CH4" area should be subscripts.

Line 72-74:What is the basis for the supplemental levels of EOZB of 0, 5, 10 and 15mg/kg in the experimental design? The trial lasted 52 days,why did choose this way?

Line 80-81: How was EOZB added? It is not stated in the dietary formula.

Line198-199:Which multiple-comparison is used?

Line213:Standard deviation rather than standard error should be used in Table 2.

Line 212,214:The P should be in italics.

Line 355, 342, 345, 351, 353, 354, 357, 359, 360: Spearman's analysis r value should be -0.5-0.5,please ask the authors to verify.

Line 377: References should be marked after "anti-inflammatory".

Line 388: References should be marked after the word "antioxidant".

********** 

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Aug 5;17(8):e0272310. doi: 10.1371/journal.pone.0272310.r002

Author response to Decision Letter 0


1 Jul 2022

Reviewer #1: Figure 1D: ANOSIN (R na P) result are too small. Please provide a better figure.

Re: We have replaced the figure and it is a little bigger in the "R and P" section.

Table 3. It would be best to standardize two digits after the dot

Re: We have modified the two digits after the dot and marked it in Table 3.

Line 277: How can you explain the predict genes of “Circulation system” , “Endrocne metabolic desease, Cytoesqueleton,....” if you provided the Microbial DNA sequencing?

Re: After the OTU abundance tables were normalised, the relationships corresponding to each OTU were compared to the KEGG and COG libraries, using PICRUSt2 to obtain the KO information and COG family information corresponding to the OTU. And calculate the abundance of each KO and the abundance of COG. Based on the information compared to the KEGG database, KO, Pathway and EC information can be obtained and the abundance of each functional class can be calculated based on the OTU abundance.

LINE 285: The figure 4 legend needs to be improve.

Re: We have modified and marked it in the article.

Line 287: The same as before. Legend needs to better described.

Re: We have modified and marked it in the article.

Line 370: The same as before. Legend needs to better described

Re: We have modified and marked it in the article.

Reviewer #2: Line 20: The description "Subgroups:" sounds a bit strange, please check with the author.

Re: We have modified and marked it in the article.

Line 44: The numbers in the "CH4" area should be subscripts.

Re: We have modified and marked it in the article.

Line 72-74:What is the basis for the supplemental levels of EOZB of 0, 5, 10 and 15mg/kg in the experimental design? The trial lasted 52 days,why did choose this way?

Re: Four gradients were established with " In vivo study on the efficacy of essential oil of Zanthoxylum bungeanum pericarp in dextran sulfate sodium-induced murine experimental colitis" and the cost of EOZB in order to select the amount of addition that would be beneficial to the healthy growth of lambs while controlling the cost. The trial period of 52 days is set based on the time limit of local lambs fattening, which is easy to combine with production practice.

Line 80-81: How was EOZB added? It is not stated in the dietary formula.

Re: A specific dose of EOZB was mixed with the concentrate to make pellets. We have modified and marked it in the article.

Line198-199:Which multiple-comparison is used?

Re: We used Duncan's method for multiple comparisons of components. We have modified and marked it in the article.

Line213:Standard deviation rather than standard error should be used in Table 2.

Re: We have modified in Table 2 and marked.

Line 212,214:The P should be in italics.

Re: We have modified all P in the full article to italics and marked it.

Line 355, 342, 345, 351, 353, 354, 357, 359, 360: Spearman's analysis r value should be -0.5-0.5, please ask the authors to verify.

Re: The range of Spearman's analysis r value is indeed -0.5-0.5. We have modified and marked it in the article.

Line 377: References should be marked after "anti-inflammatory".

Re: We have added references and revised the numbering accordingly. "[24]" is marked in the article.

Line 388: References should be marked after the word "antioxidant".

Re: We have added references and revised the numbering accordingly. "[25]" is marked in the article.

Other questions

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Re: We have revised the format according to the requirements.

2. Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Re: We have revised this section, and provided the funder's role statement.

Role of Funder statement: The funder, Cailian Wang, played an important role in the study design design. The funder, Guoshun Chen, played an important role in the decision to publish.

3. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement.

Re: We have modified the ACKNOWLEDGMENTS section.

Funding Statement:We thank for the financial support: No. 1760683; No.18YF1NA091; No. 18JR2RA032;

4. Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist."

Re: We have modified the Conflicts of Interest section.

Author Statement: The authors have declared that no competing interests exist.

5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager.

Re: We have completed this operation.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly.

Re: We have added the Supporting Information at the end of the article.

7. Please review your reference list to ensure that it is complete and correct.

Re: We checked our references again and it was compliant.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Chun Wie Chong

18 Jul 2022

Effect of Zanthoxylum bungeanum essential oil on rumen enzyme activity, microbiome, and metabolites in lambs

PONE-D-22-08057R1

Dear Dr. Wang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Chun Wie Chong

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Chun Wie Chong

20 Jul 2022

PONE-D-22-08057R1

Effect of Zanthoxylum bungeanum essential oil on rumen enzyme activity, microbiome, and metabolites in lambs

Dear Dr. Wang:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Chun Wie Chong

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Sample sequencing data statistics.

    (DOCX)

    S2 Table. Bacterial abundance at the phylum and genus level.

    (XLSX)

    S3 Table. All differential metabolites.

    (XLSX)

    S4 Table. Differential metabolites between groups.

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    A AVAILABILITY STATEMENT Metabolome raw sequence data were uploaded to the MetaboLights database and are available through accession number MTBLS3683. Microbiome raw sequence data were uploaded to the National Center for Biotechnology Information (NCBI) database and are available through accession number SRR16774443- SRR16774622.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES